Most of what you'll read about Selank online starts with the delivery route: it's a nasal spray, so it goes "straight to the brain." That claim traces back to a small number of Russian tracer studies in rats — and when you actually read them, the number that comes out is 0.16%. That is the peak fraction of an intranasal dose measured as intact peptide in rat brain tissue. It's a real result from a real lab, and it's also a long way from the marketing shorthand. This post is a look at what Selank research has genuinely measured about getting this peptide where it needs to go, what it hasn't, and what that means for Australian readers weighing up the claims. For the compound basics — sequence, tuftsin origin, mechanism — see our Selank profile.

What Is Selank, in One Paragraph

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It's the immune tetrapeptide tuftsin with a Pro-Gly-Pro tail bolted on, which slows enzymatic breakdown. It is registered in Russia as a 0.15% nasal preparation for mild anxiety and neurasthenia. Outside Russia it is not an approved medicine anywhere, and the human evidence base is three small Russian trials, the most recent of which was published in 2015.

Where the 0.16% Figure Comes From

The most useful source here is a 2019 review in Pharmaceutical Chemistry Journal by the Zolotarev group — the same lab that built the tritium-labelling methods used on these peptides. They compared four reference peptides given intranasally to rats: Pro-Gly-Pro, Pro-Gly-Pro-Leu, Semax and Selank. Peak content in rat brain reached 0.0013% (Pro-Gly-Pro-Leu), 0.13% (Semax), 0.04% (Pro-Gly-Pro) and 0.16% (Selank) of the administered dose. Corresponding peak levels in blood plasma were 0.54%, 1.69%, 1.30% and 1.04%.

Two things worth sitting with. First, Selank scored highest of the four on brain content — so within this family, the nose-to-brain argument has some support. Second, roughly six times more of the dose showed up in plasma than in brain. Intranasal delivery for these peptides is not a sealed private corridor to the CNS; it is a leaky one with a systemic spillover.

What the tracer method can and can't tell you

The method involves evenly tritium-labelled peptide, extraction from tissue, then chromatographic separation of the parent peptide from its fragments before scintillation counting. That separation step matters: without it, you'd be counting breakdown products and calling them Selank. Related work on evenly tritium-laballed peptides mapped Selank's degradation route in plasma — the pentapeptide TKPRP, tripeptide TKP and dipeptides RP and GP are major products. So the parent molecule does not hang around.

What the method can't tell you: whether 0.16% is a pharmacologically meaningful amount in a human, whether a human nose (with a much smaller olfactory epithelium relative to total nasal surface than a rat's) behaves the same way, or what the equivalent figure would be with a metered spray rather than an instilled drop. The same review names the obstacle explicitly — proteolysis by olfactory epithelium enzymes acts as a barrier, which is why researchers have tried liposomes and N-terminal acetylation to stabilise these peptides in transit.

Route Changes the Pharmacology, Not Just the Dose

This is the part usually missing from "nasal is better" claims. A comparison of intranasal versus intraperitoneal Selank in BALB/c and C57BL/6 mice found effects were both strain-dependent and route-dependent. Anxiolytic and nootropic effects appeared only in BALB/c mice — the strain with higher baseline anxiety and lower exploratory activity. And the two routes hit different receptor systems: intraperitoneal Selank increased GABA-receptor binding sites in frontal cortex by 38% with no change at hippocampal NMDA receptors, while intranasal Selank increased MK-801 (NMDA-site) binding density by 23% with no GABA-receptor effect.

If that holds, "Selank" is not one pharmacological entity with a delivery preference. The route may partly determine which mechanism you engage. This is mouse data, in two inbred strains, from a single research programme, and it has not been replicated by an independent group — treat it as a hypothesis worth testing, not an established fact.

Why Online Selank Dosing Charts Are Guesswork

Search "selank nasal spray dose" and you'll find confident tables: micrograms per actuation, half-life in minutes, percentage bioavailability, dosing intervals. Ask where those numbers come from and the trail goes cold. There is no published human pharmacokinetic study of Selank — no plasma concentration-time curve, no measured half-life in people, no bioavailability figure derived from human sampling. Rodent tracer percentages cannot be converted into a human dose, and the vendor pages quoting "15–25% CNS bioavailability" and "1–3 minute half-life" do not cite a primary human source because there isn't one. The only human-grounded dosing reference that exists is the Russian registered product's own labelling, which is a regulatory document for a product approved in one country under its own evidentiary standards. More peptides with the same evidence-shaped hole are covered across our peptides library.

Selank Australia: Is Selank Legal in Australia?

Selank is unscheduled in the Poisons Standard — it isn't listed in any schedule. That is not the same as being approved. Selank has no ARTG registration, which makes it an unapproved therapeutic good in Australia: it can't be lawfully supplied or advertised here as a therapeutic product, and access pathways for unapproved goods run through a prescriber, not a shopping cart. Products sold as "research chemicals" sit outside both the TGA's manufacturing quality framework and any assurance about what's in the bottle.

For athletes: Selank does not appear on the WADA 2026 Prohibited List. It is worth noting that non-listed status is not a safety endorsement, and the S0 "non-approved substances" catch-all is something any competing athlete should read carefully with their own anti-doping guidance before assuming clearance.

What Would Actually Move This

A single human PK study — labelled or LC-MS quantified, intranasal versus another route, with brain-exposure inference from a CNS pharmacodynamic marker — would settle more Selank arguments than another decade of rodent behavioural work. Until someone runs it, the honest position is that Selank's nose-to-brain story rests on a measured 0.16% in rats and a plausible mechanism, not on human data. Join the free updates list and we'll cover it if that changes.

FAQ

Does Selank nasal spray actually reach the brain?

In rats, yes — but a small fraction. Tracer studies report peak intact Selank in brain at about 0.16% of the intranasal dose, versus about 1.04% in blood plasma. No equivalent measurement has been published in humans.

Is Selank legal in Australia?

Selank is unscheduled in the Poisons Standard but it is an unapproved therapeutic good with no ARTG listing, so it cannot be lawfully supplied or advertised as a therapeutic product in Australia.

Is there human pharmacokinetic data for Selank?

No published human PK study exists. Half-life and bioavailability figures circulating online are not traceable to human sampling, and the human clinical record is three small Russian trials, the newest from 2015.

Is Selank banned by WADA?

Selank is not named on the WADA 2026 Prohibited List. Athletes should still check the S0 non-approved substances provision with their anti-doping authority, since Selank is not an approved medicine in Australia.

Sources

This article is information only, not medical advice. Selank is not an approved medicine in Australia and is an unapproved therapeutic good; retatrutide.net.au is independent and does not sell peptides.